Tom Decroo - Infectious Diseases

Author Information

Tom Decroo is affiliated with the Institute of Tropical Medicine, specifically within the Department of Clinical Sciences, Unit of HIV/AIDS & Infectious Diseases, located at Nationalestraat, 155 2000, Antwerp, Belgium. His work primarily focuses on infectious diseases, with significant contributions to the field of HIV/AIDS and tuberculosis research.

Research Contributions

Tom Decroo has made substantial contributions to the study of infectious diseases, particularly in the areas of HIV care and drug-resistant tuberculosis. His research includes a focus on community-based ART service delivery in Sub-Saharan Africa, the control of multidrug-resistant tuberculosis in Rwanda, and the psychiatric comorbidities associated with complex drug-resistant tuberculosis in India. He has also investigated the implications of bedaquiline-resistant tuberculosis and the management of rifampicin-resistant tuberculosis in various settings. His work highlights significant findings in the treatment and management of drug-resistant forms of tuberculosis, contributing to improved patient outcomes and care strategies.

Aliases

Tom Decroo is also known by the aliases T Decroo and T. Decroo in academic publications.

Publication and Citation Metrics

Metric	Value
Total Citation Count	2348
H-Index	26
Total Paper Count	146

Publications:

Community-Based ART Service Delivery for Key Populations in Sub-Saharan Africa: Scoping Review of Outcomes Along the Continuum of HIV Care

DOI: 10.1007/s10461-021-03568-3

Year: 2022

Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century

DOI: 10.1016/j.jctube.2022.100299

Year: 2022

Psychiatric comorbidities among patients with complex drug-resistant tuberculosis in Mumbai, India

DOI: 10.1371/journal.pone.0263759

Year: 2022

Implications of bedaquiline-resistant tuberculosis.

DOI: 10.1016/s1473-3099(22)00008-1

Year: 2022

Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study.

DOI: 10.1093/inthealth/ihac016

Year: 2022

Acquired bedaquiline resistance during the treatment of drug-resistant tuberculosis: a systematic review

DOI: 10.1093/jacamr/dlac029

Year: 2022

Acquired rifampicin resistance during first TB treatment: magnitude, relative importance, risk factors and keys to control in low-income settings

DOI: 10.1093/jacamr/dlac037

Year: 2022

Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis

DOI: 10.1183/13993003.02124-2021

Year: 2022

Person‐centred care and short oral treatment for rifampicin‐resistant tuberculosis improve retention in care in Kandahar, Afghanistan

DOI: 10.1111/tmi.13716

Year: 2022

Low Cycle Threshold Value in Xpert MTB/RIF Assay May Herald False Detection of Tuberculosis and Rifampicin Resistance: A Study of Two Cases

DOI: 10.1093/ofid/ofab034

Year: 2021

What Role Do Governments and Organizations Play?

What are the clinical features of infections caused by Flaviviridae?

How Does PCR Work?

What Are the Key Components of a One Health Approach?

What is the Roll Back Malaria Partnership?

How Can Dengue Be Prevented?

How Do HDAC Inhibitors Work?

What are the Strategies to Combat Antimicrobial Resistance?

What Are the Challenges in Controlling Culex Mosquitoes?

How is Ebola Diagnosed?

Partnered Content Networks

Relevant Topics